Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04610320

Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

Heart Transplant Failure and Rejection Clinical Trial

Official title:
A Phase 1 Study of Daratumumab-SC for Reduction of Circulating Antibodies in Patients With High Allosensitization Awaiting Heart Transplantation

Clinical Trial Summary

The purpose of this study is to test whether Daratumumab-SC, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation. These preformed antibodies limit the number of donor hearts that are compatible for the patients. If Daratumumab-SC can effectively remove preformed, donor-specific antibodies, then highly allosensitized patients will have more compatible hearts available to them, potentially decreasing transplant waitlist time and reducing mortality.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04610320
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase Phase 1
Start date July 1, 2021
Completion date January 26, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03102125 - Allograft Dysfunction in Heart Transplant Phase 4
Active, not recruiting NCT04380311 - Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant N/A
Completed NCT02109575 - Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)
Active, not recruiting NCT03386539 - Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Phase 3
Withdrawn NCT05081739 - Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation N/A
Recruiting NCT03499197 - Heart TIMING - Heart Transplantation IMagING
Recruiting NCT03538509 - Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.
Recruiting NCT03050892 - Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation N/A
Active, not recruiting NCT03373279 - Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities
Recruiting NCT05994274 - A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
Active, not recruiting NCT03575910 - HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
Withdrawn NCT04088903 - Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation Phase 1